4D Molecular Therapeutics, Inc.
FDMT
$11.21
$0.514.77%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 500.00% | 7.14% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 500.00% | 7.14% | |||
| Cost of Revenue | -1.49% | 17.82% | |||
| Gross Profit | 1.64% | -17.82% | |||
| SG&A Expenses | 2.75% | -10.95% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.67% | 10.88% | |||
| Operating Income | 0.79% | -10.88% | |||
| Income Before Tax | -4.06% | -13.94% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -4.06% | -13.94% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -4.06% | -13.94% | |||
| EBIT | 0.79% | -10.88% | |||
| EBITDA | 0.97% | -10.88% | |||
| EPS Basic | -3.69% | -13.56% | |||
| Normalized Basic EPS | 0.33% | -13.55% | |||
| EPS Diluted | -3.69% | -13.56% | |||
| Normalized Diluted EPS | 0.33% | -13.55% | |||
| Average Basic Shares Outstanding | 0.36% | 0.33% | |||
| Average Diluted Shares Outstanding | 0.36% | 0.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||